AdvanDx is launching QuickFISH, a new rapid pathogen identification test for bloodstream infections, on September 24. This product will help clinicians, hospital pharmacists and clinical microbiologists optimize antibiotic therapy much earlier for patients with bloodstream infections, including septicemia, caused by dangerous bacterial pathogens including Staphylococcus aureus and coagulase-negative staphylococci.
QuickFISH is a molecular diagnostic platform developed by AdvanDx based on proprietary PNA technology. The new platform enables 20-minute species identification of bacteria directly from positive blood cultures, allowing pathogen identification reporting at the same time as the reporting of Gram stain results.
QuickFISH allows clinicians, laboratory technicians and pharmacists to work together to provide targeted therapy, more quickly than has previously been possible with other molecular diagnostics tests and conventional methods of pathogen identification.
“Until today, the ability to provide pathogen identification in 20 minutes or less from a positive blood culture was not possible,” said Jim Coull, Ph.D, Chief Technology Officer for AdvanDx.
AdvanDx is a provider of molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. For more information visit www.AdvanDx.com.